Cornerstone Planning Group
AKBA icon

Cornerstone Planning Group’s Akebia Therapeutics AKBA Stock Holding History

Cornerstone Planning Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-413
Closed -$520 – 227
2026
Q2 		$520 Buy
+413
New +$492 ﹤0.01% 1684

Other funds holding AKBA

Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
CWA Asset Management Group
CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return
PFG Private Wealth Management
PFG Private Wealth Management Lutz, Florida $236M AUM 9.86% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Unified Investment Management
Unified Investment Management Atlanta, Georgia $114M AUM 22.27% 1-Year Est. Return
IWN
Independent Wealth Network Urbandale, Iowa $397M AUM 20.36% 1-Year Est. Return
Legacy Private Trust
Legacy Private Trust Neenah, Wisconsin $1.83B AUM 13% 1-Year Est. Return
Northern Lights Advisors
Northern Lights Advisors Seattle, Washington $192M AUM 14.28% 1-Year Est. Return
Onyx Bridge Wealth Group
Onyx Bridge Wealth Group Tarrytown, New York $1.14B AUM 18.43% 1-Year Est. Return

Cornerstone Planning Group's AKBA Position: Q3 2026 in Review

Cornerstone Planning Group sold out of Akebia Therapeutics (AKBA) in Q3 2026, closing a stake of 413 shares — an estimated $520 sold.

Cornerstone Planning Group first reported a position in AKBA in Q2 2026 and held it in 1 quarter. The position peaked at $520 in Q2 2026. 21 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.

  • Cornerstone Planning Group reported no remaining Akebia Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Cornerstone Planning Group sold 413 Akebia Therapeutics shares in Q3 2026, an estimated $520.
  • Cornerstone Planning Group first reported a position in Akebia Therapeutics in Q2 2026 and held it in 1 quarter.
  • Cornerstone Planning Group's Akebia Therapeutics position peaked at $520 in Q2 2026.
  • 21 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.

Based on Cornerstone Planning Group's 13F filing for Q3 2026, filed 16 Oct 2026.